Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Milton

Showing results (101-110 of 182) with videos related to

Pageof 19
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 19, 2016
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic LeukemiaSamer A Srour, Denái R Milton, Asad Bashey, et al.
Transplantation and Cellular Therapy|September 24, 2023
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative ConditioningJacinth Joseph, Samer A Srour, Denái R Milton, et al.
Journal of Cutaneous Pathology|March 19, 2019
Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14<sup>+</sup> and CD16<sup>+</sup> monocytes driving an innate immune responseJonathan L Curry, Alexandre Reuben, Robert Szczepaniak-Sloane, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2015
Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell TransplantationStefan O Ciurea, Peter F Thall, Denái R Milton, et al.
Leukemia|April 13, 2017
Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitorsP Kongtim, K Adekola, D R Milton, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b StudyKyaw Z Thein, Siqing Fu, Filip Janku, et al.
Archives of Pathology & Laboratory Medicine|September 27, 2023
Utility of Whole Slide Imaging for Intraoperative Consultation: Experience of a Large Academic CenterAhmed Shehabeldin, Prih Rohra, Linton D Sellen, et al.
Experimental Hematology & Oncology|December 30, 2021
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumorsKyaw Z Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Investigational New Drugs|April 28, 2021
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib studyKyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Investigational New Drugs|October 27, 2021
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib studyKyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Pageof 19

Showing results (101-110 of 182) with videos related to

Sort By:
Pageof 19
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 19, 2016
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic LeukemiaSamer A Srour, Denái R Milton, Asad Bashey, et al.
Transplantation and Cellular Therapy|September 24, 2023
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative ConditioningJacinth Joseph, Samer A Srour, Denái R Milton, et al.
Journal of Cutaneous Pathology|March 19, 2019
Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14<sup>+</sup> and CD16<sup>+</sup> monocytes driving an innate immune responseJonathan L Curry, Alexandre Reuben, Robert Szczepaniak-Sloane, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2015
Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell TransplantationStefan O Ciurea, Peter F Thall, Denái R Milton, et al.
Leukemia|April 13, 2017
Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitorsP Kongtim, K Adekola, D R Milton, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b StudyKyaw Z Thein, Siqing Fu, Filip Janku, et al.
Archives of Pathology & Laboratory Medicine|September 27, 2023
Utility of Whole Slide Imaging for Intraoperative Consultation: Experience of a Large Academic CenterAhmed Shehabeldin, Prih Rohra, Linton D Sellen, et al.
Experimental Hematology & Oncology|December 30, 2021
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumorsKyaw Z Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Investigational New Drugs|April 28, 2021
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib studyKyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Investigational New Drugs|October 27, 2021
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib studyKyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Pageof 19